Boise CME Dinner Symposium

August 19th - 2025

Bispecific Antibodies in Cancer Care: Practical Guidance for the Multidisciplinary Team

Join us at Inn at 500 Capitol in Boise on August 19th!

This interactive, 2-hour CME/CE-certified symposium will equip the multidisciplinary oncology team with practical strategies for integrating bispecific antibodies into the care of patients with cancer. Through expert-led presentations, panel discussions, case examples, and audience engagement, participants will explore:

  • Current and emerging bispecific therapies
  • Strategies for toxicity mitigation and management
  • Transitioning bispecific administration from inpatient to outpatient setting

The program aims to provide actionable insights for both academic and community-based cancer centers to address logistical, resourcing, and patient-care considerations to support the development of an outpatient clinic. 

In this how-to session, learners will:

  • Interact with national and local/regional experts in bispecific care
  • Receive tips to streamline and avoid errors in the design of an outpatient bispecific clinic
  • Fine-tune skills in the delivery of outpatient bispecifics
  • Gain insights to expedite reimbursements for outpatient bispecifics

Target Audience

This activity is designed to educate the multidisciplinary team including academic and community hematologists, oncologists, and hematology/oncology APPs, including nurse practitioners, physician assistants, pharmacists, and nurse specialists.

After participating in this education, learners should be able to:

  1. Summarize the current clinical applications of bispecific antibodies in the treatment of patients with cancer.
  2. Discuss efficacy and expected outcomes with patients who are considering treatment with a bispecific antibody.
  3. Implement appropriate dosing and administration strategies for patients undergoing treatment with bispecific antibodies in the inpatient and outpatient settings.
  4. Manage treatment-related adverse events associated with bispecific antibody therapy.
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Free Registration

Register Here

ATTENTION:
This limited-seating event is open exclusively for clinicians actively practicing in oncology as well as those cancer center employees directly involved in the design and development of outpatient clinics where bispecifics are administered to patients. No pharmaceutical representatives will be seated for this event and their registrations will be declined. We thank you for your understanding.

Program Faculty

Robert Mancini, PharmD, BCOP, FHOPA

Oncology Pharmacy Program Coordinator St. Luke's Cancer Institute Boise, ID

Mary Steinbach, DNP, APRN

Lead Advance Practice Clinician Division of Hematology University of Utah-Huntsman Cancer Institute Salt Lake City, UT

Douglas W. Sborov, MD, MS

Associate Professor Huntsman Cancer Insitute at University of Utah Salt Lake City, UT

Leila Khaddour, MD

Hematologist and Medical Oncologist Saint Alphonosus Cancer Center Boise, ID

Program Planning Committee

Jesús G. Berdeja, M.D. (content co-chair)

Director of Multiple Myeloma Research The Greco-Hainsworth Tennessee Oncology Centers for Research Nashville, TN

Charise Gleason, MSN, NP-C, AOCNP (content co-chair)

VP and Chief APP Officer Adjunct Faculty, Nell Hodgson Woodruff School of Nursing Emory Healthcare Atlanta, GA

Venue

Inn at 500 Capitol

500 S Capitol Blvd
Boise, ID 83702